Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

One-Compartment Open Model for IV Bolus Administration: General Considerations01:19

One-Compartment Open Model for IV Bolus Administration: General Considerations

213
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
213
One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution01:09

One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution

278
The one-compartment open model is a simplified approach used in pharmacokinetics to understand the distribution and elimination of a drug administered through an intravenous bolus. This model assumes rapid drug dispersal throughout the body and elimination using a first-order process. Key pharmacokinetic parameters, such as the elimination rate constant (k), half-life (t1/2), and the apparent volume of distribution (Vd), can be estimated from this model. The elimination rate is calculated...
278
Two-Compartment Open Model: IV Bolus Administration01:18

Two-Compartment Open Model: IV Bolus Administration

541
The two-compartment model for intravenous (IV) bolus administration illustrates drug distribution in the body, subdividing it into central and peripheral compartments. This model operates on the concept of two-compartment kinetics. The drug's plasma concentration shows a bi-exponential decline following IV bolus administration, signaling the presence of two disposition processes: distribution and elimination.
The disparity between drug input and the sum of drug transfer rates between...
541
Two-Compartment Open Model: IV Infusion01:15

Two-Compartment Open Model: IV Infusion

245
A two-compartment model is a vital tool in pharmacokinetics, providing an essential understanding of drug behavior, especially for those administered via zero-order intravenous infusion. This model outlines two compartments: the central compartment, where elimination occurs, and the peripheral compartment.
The model illustrates the decrease in plasma drug concentration from the central compartment with a specific equation. It shows that under steady-state conditions, the drug's input rate...
245
Compartment Models: Single-Compartment Model01:14

Compartment Models: Single-Compartment Model

2.3K
The single-compartment model serves as a simplified representation of the human body. This model assumes that the body functions as a single, well-mixed open compartment. When a drug is administered intravenously, it enters the body and quickly distributes uniformly. The drug then undergoes biotransformation and elimination, ultimately leaving the body. The volume of this compartment is referred to as the apparent volume of distribution into which the drug can uniformly distribute. In this...
2.3K
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

266
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
266

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantifying the benefits of improved operations for polio outbreak response: A model-based analysis.

Vaccine·2026
Same author

Global cessation of bivalent oral polio vaccine (bOPV): A comprehensive review of modeling studies from 2000 to 2025.

Vaccine·2026
Same author

Indirect Effects in Health Economic Models of Vaccines: Should We Include Them, and How Do We Model Them?

Applied health economics and health policy·2026
Same author

Variation in COVID-19 vaccination and adverse outcomes: a state of Georgia case study.

BMC public health·2025
Same author

Safety, tolerability, and immunogenicity of an adult-specific pneumococcal conjugate vaccine, V116, in people living with HIV (STRIDE-7): a two-part, parallel-group, randomised, active comparator-controlled, international, phase 3 trial.

The lancet. HIV·2025
Same author

A phase 3 randomized, double-blind clinical study to evaluate the safety and immunogenicity of V116 when administered concomitantly with influenza vaccine in adults 50 years of age or older.

Vaccine·2025

Related Experiment Video

Updated: Jul 10, 2025

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
13:53

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

5.0K

A mixed integer programming model for vaccine pricing within a group purchasing organization.

Zhuoting Yu1, Pinar Keskinocak1, Walter A Orenstein2

  • 1H. Milton Stewart School of Industrial and Systems Engineering, Georgia Tech, 755 Ferst Drive NW, Atlanta, GA 30332, United States of America.

Vaccine
|November 17, 2023
PubMed
Summary

Tiered pricing models can reduce disparities in medical product costs for diverse buyer groups. The optimal number of price tiers depends on buyer ability and willingness to pay, as shown in vaccine procurement case studies.

Keywords:
Equity in pricingGroup purchasingTiered pricingUniform pricingVaccine procurement

More Related Videos

Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application
04:24

Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application

Published on: June 16, 2023

1.5K
Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

1.2K

Related Experiment Videos

Last Updated: Jul 10, 2025

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
13:53

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

5.0K
Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application
04:24

Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application

Published on: June 16, 2023

1.5K
Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

1.2K

Area of Science:

  • Health economics
  • Pharmaceutical pricing
  • Global health equity

Background:

  • Procurement of life-saving medicines requires balancing affordability and health outcomes.
  • Group purchasing organizations can lower average prices but create challenges in setting individual member prices.
  • Disparities in ability and willingness to pay among buyers complicate price setting for pooled procurement.

Purpose of the Study:

  • To develop and evaluate a model for setting tiered prices for medical products for groups of buyers.
  • To quantify the performance of uniform, tiered, and differentiated pricing schemes.
  • To analyze subsidy allocation models for philanthropic support in procurement.

Main Methods:

  • A mixed integer programming model was used to optimize pricing based on buyer ability and willingness to pay.
  • The model aimed to minimize adjusted unit price disparity, with prices decreasing according to ability to pay.
  • Case studies involving Bacillus Calmette-Guerin (BCG) vaccine procurement by Gavi and PAHO were used for illustration.

Main Results:

  • Adjusted unit price disparity decreases as the number of price tiers increases.
  • A significant reduction in price disparity was observed when moving from uniform to two-tier pricing.
  • Tiered pricing was more effective in the Gavi group due to higher correlation between ability and willingness to pay.

Conclusions:

  • The study presents a quantitative model for price-setting and subsidy allocation for group procurement.
  • Tiered pricing performance is contingent on buyer-specific factors like ability and willingness to pay disparities.
  • The findings offer insights for optimizing procurement strategies in global health initiatives.